Elevated tissue factor pathway inhibitor is associated with intracerebral haemorrhage of unknown cause in young adults
, 2, 1, 3
Abstract
Clinical rationale for study. We have reported that intracerebral haemorrhage (ICH) of unknown cause at a young age is associated with lower prothrombin and factor VII and higher antithrombin activity, along with the formation of looser fibrin networks displaying enhanced lysability. Patients with mild-to-moderate bleeding of unknown cause have elevated levels of free plasma tissue factor pathway inhibitor alpha (fTFPIα), inhibiting the tissue factor–factor VII complex and prothrombinase.
Aim of study. We hypothesised that patients with an intracerebral haemorrhage (ICH) of unknown cause may also exhibit higher fTFPIα.
Material and methods. We studied 44 adults aged ≤ 50 years following ICH of unknown cause at least three months after the incident, and 47 controls matched for age, sex, BMI, and hypertension. We assessed fTFPIα levels along with plasma fibrin clot permeability, turbidity and fibrinolytic capacity, thrombin generation, coagulation factors, antithrombin, and fibrinolysis proteins.
Results. Patients following ICH had 10.8% higher median fTFPIα levels than controls (8.3 [7.6–9.5] vs. 7.4 [6.9–8.5] ng/mL; p = 0.006). fTFPIα was higher in males than in females both in the ICH group (p = 0.0004) and in controls (p = 0.007), and correlated with age (r = 0.38; p = 0.01), fibrinogen (r = –0.39, p = 0.009), PAI–1 antigen (r = –0.32, p = 0.035), and clot maximum absorbance (r = –0.30, p = 0.049), but not with other laboratory variables. Nine patients had fTFPIα levels lower the upper limit of the reference range (i.e. 11.5 ng/mL) and they had a longer lag phase of the turbidity curve (p = 0.023) and clot absorbance (p = 0.042). In univariate analysis, a 1 ng/mL increase in fTFPIα was associated with a 61% greater chance of having an ICH (OR 1.61, 95% CI 1.19–2.18) even after adjusting for potential confounders.
Conclusions. Patients with ICH of unknown cause under the age of 50 are characterised by elevated fTFPIα associated with changes in fibrin clot formation and faster PAI–1–dependent lysis.
Clinical implications. Our study might suggest a novel potential mechanism underlying ICH.
Keywords: intracerebral haemorrhagetissue factor pathway inhibitorfibrin clotblood coagulation
References
- Wafa H, Marshall I, Wolfe C, et al. Burden of intracerebral haemorrhage in Europe: forecasting incidence and mortality between 2019 and 2050. The Lancet Regional Health - Europe. 2024; 38: 100842.
- Tatlisumak T, Cucchiara B, Kuroda S, et al. Nontraumatic intracerebral haemorrhage in young adults. Nat Rev Neurol. 2018; 14(4): 237–250.
- Marietta M, Pedrazzi P, Girardis M, et al. Intracerebral haemorrhage: an often neglected medical emergency. Intern Emerg Med. 2007; 2(1): 38–45.
- Łopatka P, Błaż M, Nowicki G, et al. Altered fibrin clot phenotype in young adults with intracerebral hemorrhage of unknown cause: A case-control study. Thromb Res. 2024; 240: 109062.
- Mehic D, Colling M, Pabinger I, et al. Natural anticoagulants: A missing link in mild to moderate bleeding tendencies. Haemophilia. 2021; 27(5): 701–709.
- Mast AE, Ruf W. Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy. J Thromb Haemost. 2022; 20(6): 1290–1300.
- Maroney SA, Ellery PE, Mast AE. Alternatively spliced isoforms of tissue factor pathway inhibitor. Thromb Res. 2010; 125 Suppl 1: S52–S56.
- Mast AE. Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein. Arterioscler Thromb Vasc Biol. 2016; 36(1): 9–14.
- Broze GJ, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci (Landmark Ed). 2012; 17(1): 262–280.
- Mehic D, Tolios A, Hofer S, et al. Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency. Blood Adv. 2021; 5(2): 391–398.
- Englisch C, Moik F, Thaler J, et al. Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer. Haematologica. 2024; 109(4): 1128–1136.
- Zakai NA, Lutsey PL, Folsom AR, et al. Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology. Thromb Haemost. 2010; 104(2): 207–212.
- Suzuki M, Kudo A, Otawara Y, et al. Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage. Neurosurgery. 1999; 44(3): 487–93; discussion 493.
- Schmidt ML, Gamerman S, Smith HE, et al. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. Am J Hematol. 1994; 47(1): 36–40.
- Meretoja A, Strbian D, Putaala J, et al. SMASH-U: a proposal for etiologic classification of intracerebral hemorrhage. Stroke. 2012; 43(10): 2592–2597.
- Błaż M, Natorska J, Bembenek JP, et al. Elevated lipopolysaccharide level is largely driven by time since symptom onset in acute ischemic stroke: the impact on clinical outcomes. J Thromb Haemost. 2024; 22(11): 3161–3171.
- Matsushita T, Shapiro A, Abraham A, et al. explorer7 Investigators. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023; 389(9): 783–794.
- Coppola R, Cristilli P, Cugno M, et al. The increase with age of the components of the tissue factor coagulation pathway is gender-dependent. Blood Coagul Fibrinolysis. 1995; 6(5): 433–437.
- Peterson JA, Gupta S, Martinez ND, et al. Factor V east Texas variant causes bleeding in a three-generation family. J Thromb Haemost. 2022; 20(3): 565–573.
- Cunha MLR, Bakhtiari K, Peter J, et al. A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. Blood. 2015; 125(11): 1822–1825.
- Sterenstein A, Garg R. The impact of sex on epidemiology, management, and outcome of spontaneous intracerebral hemorrhage (sICH). J Stroke Cerebrovasc Dis. 2024; 33(7): 107755.
- Koivunen RJ, Satopää J, Meretoja A, et al. Incidence, risk factors, etiology, severity and short-term outcome of non-traumatic intracerebral hemorrhage in young adults. Eur J Neurol. 2015; 22(1): 123–132.
- Gedansky A, Jarvis P, Yu D, et al. Intracerebral Hemorrhage in a Young Urban Population: Etiologies and Outcomes in Patients 50 and Younger. J Stroke Cerebrovasc Dis. 2019; 28(10): 104295.
- Cheda M, Kuczyńska M, Dąbrowska I, et al. Haemorrhagic intracranial complications associated with vaccine-induced thrombocytopenia or central venous thrombosis after COVID-19 vaccination: postulated underlying mechanisms with literature and case review. Neurol Neurochir Pol. 2024; 58(5): 484–489.
- Lasek-Bal A, Członkowska A, Qureshi MM, et al. International study: Global impact of COVID-19 on stroke care - the Polish contribution. Neurol Neurochir Pol. 2023; 57(1): 136–139.
- de Maat MP. Effects of diet, drugs, and genes on plasma fibrinogen levels. Ann N Y Acad Sci. 2001; 936: 509–521.
- Undas A. Laboratory Testing for Fibrinogen Disorders: From Routine Investigations to Research Studies. Semin Thromb Hemost. 2024 [Epub ahead of print].
- Pieters M, Guthold M, Nunes CM, et al. Interpretation and Validation of Maximum Absorbance Data Obtained from Turbidimetry Analysis of Plasma Clots. Thromb Haemost. 2020; 120(1): 44–54.
- Saes JL, Schols SEM, van Heerde WL, et al. Hemorrhagic disorders of fibrinolysis: a clinical review. J Thromb Haemost. 2018 [Epub ahead of print].
- Brummel-Ziedins KE, Orfeo T, Rosendaal FR, et al. Empirical and theoretical phenotypic discrimination. J Thromb Haemost. 2009; 7 Suppl 1(Suppl 1): 181–186.
- Siudut J, Iwaniec T, Plens K, et al. Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects. Thromb Res. 2021; 197: 1–7.
- Mehndiratta MM, Agarwal P, Sen K, et al. Stroke in young adults: a study from a university hospital in north India. Med Sci Monit. 2004; 10(9): 535–541.
- Stolarz-Skrzypek K, Czarnecka D. Resistant hypertension: challenges in everyday practice. Pol Arch Intern Med. 2023; 133(12).
- Algharably EA, Meinert F, Januszewicz A, et al. Understanding the impact of alcohol on blood pressure and hypertension: From moderate to excessive drinking. Kardiol Pol. 2024; 82(1): 10–18.
